Bristol-Myers Squibb

Manager, Cell Therapy Supply Chain

Devens, Massachusetts, United States

Auto‑apply with AI Apply

$130,000 – $170,000Compensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates should possess experience in a commercial CGMP manufacturing facility within the Biotechnology industry, demonstrating autonomy in decision-making, technical expertise, leadership capability, and the ability to manage a team and execute against schedules. Proficiency with SAP transactions and workflows is also expected.

Responsibilities

The Manager, Cell Therapy Supply Chain will execute against scheduled activities, make decisions, and allocate resources accordingly within and across departments, oversee floor operations during the second shift, manage the receipt and processing of incoming patient apheresis material with corresponding documentation in SAP, perform and oversee drug product packaging into cryogenic shipper for shipment to patient, support material kitting operations to ensure continuous supply of raw materials, and provide support with SAP transactions and workflows with direct and indirect impact on Manufacturing.

Skills

SAP

CGMP

Biotechnology

Supply Chain Management

Team Management

Scheduling

Resource Allocation

Drug Product Packaging

Cryogenic Shippers

Material Kitting

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Key Metrics

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free